If the scale stopped moving the way it used to, you are not imagining a midlife shift. Many women notice weight that is harder to change around perimenopause and menopause, and more of it settling at the middle. GLP-1 medicines—and related drugs such as tirzepatide—are now part of everyday conversation. They are prescription medicines some clinicians use for type 2 diabetes or chronic weight management. They are not a menopause treatment, and they are not something this article can recommend you start.
A 2026 research conversation you may see in headlines is whether menopause hormone therapy, when a clinician has already prescribed it for other reasons, is associated with a different weight-loss response on these medicines. That is a question for a visit—not a protocol, and not a reason to add either medicine on your own.
Why did my usual weight habits stop working after 45?
Mayo Clinic notes that weight gain often begins in perimenopause and commonly continues through the 50s, at about 1.5 pounds a year for many women. Hormonal change tends to shift where fat is stored—more often the belly—while aging, less muscle, sleep loss, and everyday movement also change how the body uses energy. Hormone therapy, Mayo Clinic writes, has not been shown to cause weight loss. The Menopause Society’s 2022 position statement discusses it mainly for vasomotor symptoms and genitourinary syndrome—not as a weight-loss medicine.
None of this means a GLP-1 is required, or that food and movement no longer matter. It means the midlife picture is more than willpower. It is reasonable to bring the whole picture—sleep, hot flashes, mood, medications, and the number on the scale—to a clinician who knows your history.
What are GLP-1 medicines, in plain language?
GLP-1 receptor agonists are a class of prescription drugs. Some products that contain semaglutide are FDA-approved to reduce excess body weight in adults with obesity, or with overweight plus a related condition, and for certain other labeled uses. Tirzepatide products are a related class (they also act on a second gut hormone, GIP). One tirzepatide product is FDA-approved for chronic weight management; another is approved for type 2 diabetes.
These medicines can have side effects, including gastrointestinal symptoms, and they are not right for everyone. They require a prescription, follow-up, and a plan that is yours—not a social-media protocol. GoBloomWell does not sell, prescribe, or recommend starting them.
Is combining a GLP-1 with hormone therapy a menopause protocol?
No. In January 2026, a Mayo Clinic team published a retrospective (looking-back) study in The Lancet Obstetrics, Gynaecology, & Women's Health. They reviewed 120 postmenopausal women who had already been taking tirzepatide for at least 12 months and compared those also using menopausal hormone therapy with similar women who were not. In that observational study, women using both lost more weight than women on tirzepatide alone. The senior author, endocrinologist Maria Daniela Hurtado Andrade, M.D., Ph.D., said clearly: because this was not a randomized trial, “we cannot say hormone therapy caused additional weight loss.” Women already using hormone therapy may have been sleeping better, moving more, or living differently in ways the study could not fully separate.
A 2024 retrospective study in Menopause, also from Mayo Clinic researchers, found a similar pattern with semaglutide: among postmenopausal women already treated with semaglutide, those using hormone therapy had a greater average weight-loss percentage at 3, 6, 9, and 12 months. That study was also observational, with a small hormone-therapy group (16 women on hormone therapy and 90 without), and the authors called for larger studies.
What 2026 headlines sometimes skip: association is not a prescription. If you are already on one of these medicines, or already on hormone therapy, the useful move is to ask your clinician how the two might interact for you—including muscle, nutrition, bone, and how you feel day to day. If you are on neither, this research is not a reason to start both.
What should I watch besides the number on the scale?
Midlife weight conversations are often really body-composition conversations. Muscle typically declines with age. Sleep, night sweats, and fatigue can change how you eat and move. If a clinician ever discusses a GLP-1 with you, questions about protein, strength training, and how you will be followed are part of ordinary care—not extras.
Keeping a short log of weight, waist, sleep, hot flashes, appetite, and energy can make a visit more concrete. A one-page doctor report is not a diagnosis. It is a way to show patterns without relying on memory in a short appointment.
Questions to take to your clinician
- Given my history, is a GLP-1 even on the table for me—and if not, what else is?
- If I am already on a GLP-1 or already on hormone therapy, how should we think about the other, without treating headlines as a protocol?
- What side effects or follow-up matter for someone my age?
- How should we watch muscle, bone, and nutrition, not only pounds?
- What would make you pause or stop a medicine if we ever start one?
This is not a diagnosis, and it is not a recommendation to start a GLP-1, hormone therapy, or any supplement. Talk with your doctor about what belongs in your plan. A daily tracker and a sample doctor report can help you walk in with dates, symptoms, and questions instead of a vague “nothing is working.” That is the job of a companion app. Treatment stays with your clinician.
Sources
- Mayo Clinic News Network. “New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause.” January 22, 2026. https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause/
- Hurtado MD, et al. “Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.” Menopause. 2024. https://doi.org/10.1097/GME.0000000000002310
- Mayo Clinic Staff. “The reality of menopause and weight gain.” Updated July 19, 2026. https://www.mayoclinic.org/healthy-lifestyle/womens-health/in-depth/menopause-weight-gain/art-20046058
- The North American Menopause Society. “The 2022 hormone therapy position statement of The North American Menopause Society.” Menopause. 2022. https://menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- DailyMed / U.S. National Library of Medicine. WEGOVY (semaglutide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Educational only. Not medical advice. Last reviewed August 2026.
Not medical advice. Always talk to your doctor.